Results 101 to 110 of about 24,759 (261)

Doxapram Exposure Was Not Associated With Adverse Neurodevelopmental Outcomes in Very Low Birth Weight Infants: A Monocentric Retrospective Cohort Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim Doxapram is used as an additional therapy for apnea of prematurity when standard treatments such as caffeine or continuous positive airway pressure are insufficient, but its impact on long‐term neurodevelopment remains uncertain. This study evaluated the association between Doxapram exposure and neurodevelopmental outcomes in very low ...
Thomas Müller, Alexandros Rahn, Sabine Pirr, Corinna Peter, Carolin Böhne, Bettina Bohnhorst   +5 more
wiley   +1 more source

Letter to the Editor—Comment on “Erythropoietic Protoporphyria and Surgery: A Case of Successful Mastectomy With Perioperative Light Shielding Strategies Based on Light‐Induced Hemolytic Threshold Assessment”

The Journal of Dermatology, EarlyView.
Ingeborg de Rover, N. Chantal Peltenburg, Johan C. M. Sweep, Janneke G. Langendonk   +3 more
wiley   +1 more source

Methaemoglobinaemia: From pathophysiology to contemporary clinical management

British Journal of Haematology, EarlyView.
Summary Methaemoglobin (MetHb) is an oxidised form of haemoglobin (Hb) unable to bind oxygen. Raised levels of MetHb reduce the blood's oxygen‐carrying capacity, causing potentially severe hypoxaemia and possible death. The condition arises from three main pathologies: mutations in globin genes causing Haemoglobin‐M, inherited deficiency of the enzyme ...
Alexander J. Twine, David C. Rees
wiley   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

The role of protein arginine methyltransferases in sickle cell‐mediated neurovascular impairments in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...
Julia Zaccarelli‐Magalhães, Mariana Sayuri Berto Udo, Drew James Smith, Julia Langman, Luiz Henrique Matuguma, Guilherme Nagamine Gomes, Peter Rodriguez, Ammar Husan, Quanguang Zhang, Christopher G. Kevil, Cristiane Teresinha Citadin, Hung Wen Lin   +11 more
wiley   +1 more source

Human Embryonic Stem Cell‐Derived Immunity‐And‐Matrix‐Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1‐Mediated Collagen Degradation

Cell Proliferation, EarlyView.
Human embryonic stem cell‐derived Immunity‐and‐Matrix‐Regulatory Cells (IMRCs) effectively attenuate pulmonary fibrosis by secreting Matrix Metalloproteinase‐1 (MMP1), which directly degrades excess collagen I in the extracellular matrix. By directly degrading collagen I, IMRCs reverse ECM stiffness, suppress myofibroblast activation, and promote a ...
Zhongwen Li, Dingyun Song, Faguo Sun, Licheng Song, Bin An, Tingting Gao, Jingjing Liu, Kan Zhang, Kaidi Liu, Kaiwei Wu, Yajing Li, Yi Yang, Yaru Liu, Ruofan Su, Zai Wang, Tiemei Zhao, Huaiyong Chen, Li Xiao, Liang Peng, Liu Wang, Wei Li, Lixin Xie, Jie Hao, Huaping Dai, Jun Wu   +24 more
wiley   +1 more source

Mechanisms of Thrombocytosis in Iron‐Deficiency Anemia

European Journal of Haematology, EarlyView.
ABSTRACT Iron‐deficiency anemia is frequently accompanied by reactive thrombocytosis, yet the mechanisms underlying this association remain incompletely understood. Beyond impaired erythropoiesis, iron availability has emerged as an active regulator of hematopoietic lineage decisions.
João Vitor Facco, Diane S. Krause, Sara T. Olalla Saad   +2 more
wiley   +1 more source

Should we restrict erythrocyte transfusion in early goal directed protocols? [PDF]

BMC Anesthesiol, 2015
Meybohm P, Shander A, Zacharowski K.
europepmc   +1 more source

Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes

European Journal of Haematology, EarlyView.
ABSTRACT Aims Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired, non‐malignant haematological disorder that, if left untreated, can lead to significant morbidity. This systematic literature review (SLR) summarized real‐world evidence (RWE) for pegcetacoplan, a complement 3/3b inhibitor (C3i) available since 2021.
Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Vikte Lionikaite, Elisabetta Metafuni   +4 more
wiley   +1 more source

Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study

European Journal of Haematology, EarlyView.
ABSTRACT Background Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines ...
Allison Mo, Le Thi Phuong Thao, Cameron Wellard, Erica M. Wood, Jake Shortt, Zoe K. McQuilten   +5 more
wiley   +1 more source